


## Supplemental Figure 4

**A**

CO-1686 dose	Route	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (hr)	T <sub>1/2</sub> (hr)	V <sub>ss</sub> (L/kg)	Cl (L/hr/kg)	AUC <sub>last</sub> (hr*ng/mL)	OBA (%F)
5mg/kg	IV	14300	0.083	0.82	0.34	0.53	9500	-
20mg/kg	PO	10500	0.25	2.6	-	-	24800	65

**B**



**SI figure 4.** (A) Mean pharmacokinetic parameters following intravenous or oral administration of CO-1686 in female Nu/Nu mice. Abbreviations: AUC<sub>last</sub>, area under the curve to last observed plasma concentration; Cl, clearance; C<sub>max</sub>, maximum concentration; IV, intravenous; PO, oral gavage by mouth; OBA, oral bioavailability; T<sub>1/2</sub>, terminal elimination half-life; T<sub>max</sub>, time to maximum concentration; V<sub>ss</sub>, volume of distribution at steady state. (B) Mean plasma concentrations and standard error of the mean of CO-1686 following intravenous or oral administration in female Nu/Nu mice (n=3 mice/time point ±SEM).